A61K 31/4725
Containing further heterocyclic rings
Official title: containing further heterocyclic rings
A61K31/4725 (Containing further heterocyclic rings) appears on 1,132 US grants and 2,079 published applications in this corpus.
Search patents in A61K- Granted patents
- 1,132
- Published applications
- 2,079
- Assignees
- 877
- Inventors
- 5,655
- Latest grant
- 8 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 2 | 0 |
| 1994 | 1 | 0 |
| 1995 | 4 | 0 |
| 1996 | 5 | 0 |
| 1997 | 15 | 0 |
| 1998 | 9 | 0 |
| 1999 | 9 | 0 |
| 2000 | 9 | 0 |
| 2001 | 7 | 4 |
| 2002 | 12 | 8 |
| 2003 | 17 | 27 |
| 2004 | 2 | 30 |
| 2005 | 13 | 24 |
| 2006 | 10 | 24 |
| 2007 | 5 | 26 |
| 2008 | 12 | 32 |
| 2009 | 11 | 47 |
| 2010 | 17 | 60 |
| 2011 | 32 | 56 |
| 2012 | 32 | 62 |
| 2013 | 47 | 95 |
| 2014 | 66 | 110 |
| 2015 | 86 | 159 |
| 2016 | 82 | 122 |
| 2017 | 101 | 110 |
| 2018 | 73 | 113 |
| 2019 | 82 | 118 |
| 2020 | 74 | 92 |
| 2021 | 55 | 106 |
| 2022 | 55 | 89 |
| 2023 | 50 | 124 |
| 2024 | 33 | 148 |
| 2025 | 55 | 151 |
| 2026 | 49 | 142 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Multiparticulate pharmaceutical composition of tamsulosin and solifenacin8 Sep 2026US 12,728,106 B2Zim Laboratories Limited
- Coronavirus main protease inhibitors and methods using same8 Sep 2026US 12,729,190 B2Baylor College of Medicine
- 5-amino-6,8-dihydro-1H-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide derivatives as MTA-cooperative inhibitors of PRMT51 Sep 2026US 12,723,048 B2BeOne Medicines | GmbH
- Cancer combination therapies utilizing a nicotinamide phosphoribosyltransferase inhibitor in combination with a nicotinamide adenine dinucleotide salvage pathway precursor25 Aug 2026US 12,714,722 B2Fred Hutchinson Cancer Center
- TSG6 polypeptide fragment for dry eye disease4 Aug 2026US 12,697,368 B2The University of Manchester
- Composition for removing and inhibiting senescent cells, and uses thereof8 Oct 2026US 2026/0306460 A1Lifeceutix Co., Ltd.
- Lifitegrast-containing ink binder for ophthalmic devices8 Oct 2026US 2026/0306478 A1Bausch + Lomb Ireland Limited
- Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors8 Oct 2026US 2026/0306505 A1BioAxone BioSciences, Inc.
- Triazolyl-containing compounds8 Oct 2026US 2026/0308146 A1Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Surface modified ophthalmic devices1 Oct 2026US 2026/0294680 A1Bausch + Lomb Ireland Limited
Most cited
By later US patents
- Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase209US 5,409,930 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1995
- Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof170US 7,074,801 B1Eisai Co., Ltd. · 2006
- Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase132US 5,656,643 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1997
- Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers124US 6,045,829 AElan Pharma International Limited · 2000
- Anti-estrogenic compounds and compositions119US 5,395,842 AEndorecherche, Inc. · 1995